The pharma hasn’t yet revealed what kind of job cuts might be involved in the plan, which will help it absorb the coming loss ...

Initial public offerings make the biotechnology industry tick. Stock listings give young companies the funding they need to develop their drugs, and their venture backers an opportunity to earn a ...

High-level turnover has introduced uncertainty about how quickly the FDA’s agency-wide AI strategy will move forward.

Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell deficiency.

Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with ...

The deal gives Argenx a drug prospect aimed at the protein target CD122, an approach that’s recently gained traction among ...

Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more ...

Most recently the leader of buzzy startup Tessera Therapeutics, Severino will look to improve the fortunes of a company ...

The decision to no longer seek approval of amlitelimab is the latest setback for a treatment once hailed as a future ...

Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a ...

The startup is the first gene editing company to price an IPO in more than two years, though it banked far less than most ...

In a victory for Robert F. Kennedy Jr.’s “MAHA” agenda, panelists narrowly recommended broader use of six of the seven ...